Post Categories
EU Clinical Trial Regulation 536/2014 and CTIS: Common Questions and Answers
March 20, 2024
As reported in our previous CTIS-related blog post, the way clinical trials are documented in the European Union (EU) is changing. By January 31,…
Customized Therapies Offer Hope for Patients with Ultra-Rare Genetic Diseases
March 18, 2024
Leveraging rapid developments in gene therapy, researchers are designing new ways to target ultra-rare genetic diseases with treatments tailored to a patient’s specific genetic…
Navigating Changes to EU Clinical Trial Management: What You Need to Know
March 13, 2024
The face of clinical trials in the European Union (EU) is changing. By January 31, 2025, all ongoing clinical trials must move to the…
Psychoactive Drug Ibogaine Has Transformative Effects for Veterans with Traumatic Brain Injury
March 11, 2024
Traumatic brain injuries (TBIs), commonly experienced by military personnel, often incur deep damage and invisible scars. Such injuries are significant contributors to post-traumatic stress…
The Link Between Obesity Drugs and Brain Health
March 6, 2024
Glucagon-like peptide-1 (GLP-1) receptor agonists are arguably the hottest topic in medical innovation. The drugs semaglutide and tirzepatide, known under brand names like Ozempic,…
Advances in Treating Autoimmune Diseases Focus on Restoring Immune Tolerance
March 4, 2024
For decades, the battle against autoimmune diseases like type 1 diabetes, lupus, and multiple sclerosis has been an uphill struggle. Conventional treatments most often…
Research Challenges Conventional Wisdom on Obesity and Mortality
February 26, 2024
Research using data from a large U.S. health survey has disrupted conventional thinking about body mass index (BMI) and its role in predicting all-cause…
Fighting Disease Transmission From Humans to Chimpanzees: A Critical Conservation Effort
February 19, 2024
When a human virus was identified as the source of a 2017 respiratory disease outbreak among chimps at Uganda’s Kibale National Park, the discovery…
Could Newly Identified Genetic Variant Hold the Key to Metabolic Health?
February 14, 2024
Lurking among the vast genetic holdings of the UK Biobank data, researchers uncovered a potential gem — a gene variant linked to cardiometabolic health….
“It’s Incredible” — Breakthrough Spinal Implant Restores Walking Ability Lost Due to Parkinson’s Disease
February 12, 2024
Marc, a 63-year-old from Bordeaux, France, has lived with Parkinson’s disease for more than two decades. The disease had increasingly hindered his mobility, causing…
“Like Day and Night” — CRISPR’s Life-Changing Potential in Sickle Cell Disease
February 5, 2024
A groundbreaking gene editing therapy for sickle cell disease from CRISPR Therapeutics and Vertex Pharmaceuticals has received approval from the U.S. Food and Drug…
Pharma’s Expanding Arsenal Against Mosquitoes — the World’s Deadliest Creatures
January 29, 2024
Although mosquitoes measure less than an inch and weigh a mere 2.5 milligrams, the disease burdens they carry make them the “deadliest animal on…
Advancing CRISPR-Based Treatment for Rare Swelling Disease
September 30, 2024
Intellia Therapeutics, based in Cambridge, Massachusetts, reported promising results from the Phase II clinical trial of NTLA-2002, a CRISPR-based therapy targeting hereditary angioedema (HAE),…
Advancing Phase 3 Trials for ADC Cancer Therapies
September 25, 2024
Antibody-drug conjugates (ADCs) are being studied in various diseases, including cancer, autoimmune and infectious diseases. In cancer, ADCs are made up of a monoclonal…
Battling COVID in the Lab: Mini-Lungs Yield Insights and Potential Prevention Pathways
September 23, 2024
Over the past five years, scientists have slowly gained a better understanding of SARS-CoV-2, the virus responsible for the COVID-19 pandemic. Despite our knowledge…
New Cancer Treatment Modality Goes into Phase I
September 18, 2024
Prostate cancer is the second most common cancer in men worldwide, making the search for effective treatments an urgent imperative for the medical community….
Breaking Ground in Cancer Treatment: First T-Cell Therapy Approved for Solid Tumors
September 16, 2024
Tecelra®, the first engineered T-cell therapy for solid tumors, has received approval from the Food and Drug Administration (FDA) for advanced MAGE-A4+ synovial sarcoma…
Medicare Price Cuts Promise Relief to Seniors
September 9, 2024
In a historic move, the White House announced steep price reductions for ten prescription drugs under Medicare thanks to the Inflation Reduction Act (IRA)….
Introduction Researchers are developing novel, safer treatments for cancer, but bringing new oncology therapies to market is challenging. This white paper will examine the…
Introduction As global obesity rates continue to rise, the search for effective treatments is more critical than ever. Obesity is associated with an increased…
Introduction Changes in how clinical trials are managed in the European Union (EU), mandated by the European Union Clinical Trial Regulation 536/2014 (EU CTR),…
TAIPEI, Taiwan—(BUSINESS WIRE)—QPS, a leading global contract research organization (CRO) specializing in preclinical and clinical drug development services, is pleased to announce the expansion…
QPS India has achieved another significant milestone by successfully completing a scheduled inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA) from…
QPS Selects Ryght AI as an Exclusive AI Partner for Clinical Trial Optimization and Automation while adding to Ryght’s global site network. Laguna Beach,…
